Tedalinab（Cat No.:R028194）is a synthetic cannabinoid receptor type 2 (CB2) agonist investigated for its anti-inflammatory and analgesic properties. By selectively activating CB2 receptors, predominantly expressed in immune cells, it modulates cytokine release and reduces inflammatory signaling without the psychoactive effects associated with CB1 activation. Preclinical and early clinical studies have explored its potential in treating autoimmune diseases, neuropathic pain, and other inflammatory conditions. Tedalinab remains an important research compound in immunology and pain management, providing insights into therapeutic strategies targeting the endocannabinoid system with improved safety and specificity.